公开(公告)号：US20220031697A1

公开(公告)日：2022-02-03

申请号：US17401600

申请日：2021-08-13

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Sebastien JEAY ,  Astrid JULLION ,  Christophe MEILLE ,  Jens WUERTHNER ,  Claire Fabre

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/553 ,  A61K31/706 ,  A61K31/7068 ,  A61K45/06

Abstract: The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201), or a pharmaceutically acceptable non-covalent derivative thereof, for use in the treatment of patients with hematological tumors, wherein the drug is administered by an extended low dose dosing regimen.

公开(公告)号：US20200281925A1

公开(公告)日：2020-09-10

申请号：US16494927

申请日：2018-03-29

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nesol GURREIO ,  Senastien JEAY ,  Astrid JULLION ,  Christophe MEILLE ,  Jens WUERTHNER

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/553 ,  A61K31/706 ,  A61K31/7068 ,  A61P35/00

Abstract: The present invention relates to the HDM2-p53 interaction inhibitors (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one (HDM201), or a pharmaceutically acceptable non-covalent derivative thereof, for use in the treatment of patients with hematological tumors, wherein the drug is administered by an extended low dose dosing regimen.

公开(公告)号：US20210363254A1

公开(公告)日：2021-11-25

申请号：US16981828

申请日：2019-03-18

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Ensar HALILOVIC ,  Sebastien JEAY ,  Astrid JULLION ,  Jinsheng LIANG ,  Christophe MEILLE ,  Hui-Qin WANG ,  Jens WUERTHNER

IPC: C07K16/28 ,  A61P35/00 ,  C07D487/04

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).